论文部分内容阅读
目的研究应用阿托伐他汀(atorvastatin)对急性冠状动脉综合征(acute coronary syn-dromes,ACS)患者减少炎症反应、稳定斑块的作用。方法选定ACS患者60例,稳定型心绞痛(SA)患者30例及正常对照组30例。随机将ACS患者分为阿托伐他汀治疗组(30例)和常规治疗组(30例),比较各组间血清白介素-6(IL-6)、白介素-8(IL-8)及超敏C反应蛋白(sCRP)的水平变化。结果ACS组与SA组及正常对照组之间血清IL-6、IL-8及sCRP水平相比差异有统计学意义,两治疗组治疗后血清IL-6、IL-8及sCRP水平相比差异有统计学意义。结论阿托伐他汀可降低ACS患者血清IL-6、IL-8及sCRP水平,减少冠状动脉粥样斑块基质成分的降解和炎症反应,从而起到稳定动脉粥样硬化斑块的作用。
Objective To study the effect of atorvastatin on reducing inflammation and stabilizing plaque in patients with acute coronary syndrome (ACS). Methods Sixty ACS patients, 30 patients with stable angina pectoris (SA) and 30 normal controls were enrolled in this study. ACS patients were randomly divided into atorvastatin group (30 cases) and routine treatment group (30 cases). The levels of serum interleukin-6, IL-8 and hypersensitivity C-reactive protein (sCRP) level changes. Results There was significant difference in serum IL-6, IL-8 and sCRP levels between ACS group and SA group and normal control group. There was significant difference in serum IL-6, IL-8 and sCRP levels between two groups There is statistical significance. Conclusions Atorvastatin can reduce the level of serum IL-6, IL-8 and sCRP in ACS patients and reduce the degradation and inflammation of matrix components in coronary atherosclerotic plaque, thus stabilizing atherosclerotic plaque.